Connect public, paid and private patent data with Google Patents Public Datasets

Tissue implant

Download PDF

Info

Publication number
US20010016772A1
US20010016772A1 US09770620 US77062001A US2001016772A1 US 20010016772 A1 US20010016772 A1 US 20010016772A1 US 09770620 US09770620 US 09770620 US 77062001 A US77062001 A US 77062001A US 2001016772 A1 US2001016772 A1 US 2001016772A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
cells
matrix
component
tissue
implant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09770620
Inventor
David Lee
Daniel Bader
Myra Stephens
Original Assignee
Lee David A.
Bader Daniel L.
Stephens Myra D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843Connective tissue
    • A61L27/3852Cartilage, e.g. meniscus
    • A61L27/3856Intervertebral discs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843Connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843Connective tissue
    • A61L27/3852Cartilage, e.g. meniscus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/48Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56Porous materials, e.g. foams or sponges
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58Materials at least partially resorbable by the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/06Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus

Abstract

A biochemical implant is described which comprises at least two matrix components. The first matrix component is composed of collagen with a porous macrostructure with the ability to withstand tensile or shear forces. The second matrix component is a hydrated alginate gel which substantially fills the porous macrostructure of the first component and exerts a swelling pressure. The implant additionally comprises a population of cells comprising chondrocytes, fibrochondrocytes, fibroblasts or osteoblasts, or precursors thereof.

Description

  • [0001]
    The present invention relates to a tissue implant for use in damaged load-bearing cartilaginous tissue, such as the meniscus and articular cartilage.
  • [0002]
    Many non-calcified skeletal connective tissues such as articular cartilage, menisci, ligaments, tendons and intervertebral disc have a mechanical function and, as such, are subjected to dynamic mechanical loading during physiological activity. For example, joint forces are considerable during normal physiological activities and commonly exceed 2000 N or three times body weight and occur repetitively approximately 1 million times per year. Thus articular cartilage will be commonly subjected to contact stresses exceeding 5 MPa.
  • [0003]
    The cartilaginous tissues are composed of cells embedded within an extensive extracellular matrix. The functional behaviour of these tissues is best understood when it is considered as biphasic consisting of a fluid phase of interstitial water containing dissolved inorganic salts and a solid phase containing the collagen-proteoglycan organic solid matrix. The two phases together permit fluid flow through the permeable solid phase. It is the physicochemical interaction of the various components of the extracellular matrix which is responsible for the mechanical properties of the healthy tissues. For example in articular cartilage, there is a physico-chemical equilibrium between the osmotic swelling pressure (Pswelling) of the proteoglycan gel which is balanced by the hydrostatic pressures (Pelastic) due to the tensile stresses generated within the collagen fibre network. This balance exists even in unloaded articular cartilage. It is altered when the tissue is loaded in compression by an applied hydrostatic pressure (Papplied) resulting in a net pressure differential (Δp) and fluid flow away from the compressed tissue. The appropriate equation is given by
  • Δp=P applied+(P elastic −P swelling)
  • [0004]
    This fluid flow will result in an increased proteoglycan concentration within the tissue and a change in the relative magnitudes of the stresses in the two solid components of articular cartilage. If the compressive load remains constant the rate of fluid flow decreases with time and eventually reduces to zero at a new state of equilibrium. This timne-dependent creep behaviour is characteristic of all viscoelastic soft tissues.
  • [0005]
    The cells, although occupying less than 10% of the tissue volume, are necessary for the synthesis and maintenance of matrix levels and are, therefore, crucial to the structural integrity and function of the tissue. It is known that the cells, whether chondrocytes in cartilage, fibrochondrocytes in menisci, or tenocytes and fibroblasts in tendon and ligament respectively, are able to alter their metabolic activity in response to applied loads. Both the level of strain applied and the dynamic frequency are known to be important in determining this response. These processes are believed to be major factors in determining cellular activity in these tissues.
  • [0006]
    The mechanisms by which cells detect and respond to mechanical load are termed mechanotransduction pathways and are complex and poorly understood. mechanotransduction events may be resolved into extracellular components including cell deformation, hydrostatic pressures and streaming potentials, followed by intracellular signalling events such as intracellular calcium fluxes, cAMP production and cytoskeletal alterations which finally lead to altered effector cell response. However, understanding such mechanisms has been complicated by the need to investigate the processes at a number of different levels, including the cellular level.
  • [0007]
    Injuries to soft tissues are extremely common in hospital clinics. Indeed, soft tissue replacements amount to an estimated 35% of the world market for all medical devices (Materials Technology Foresight in Biomaterials, Institute of Materials, London (1995).
  • [0008]
    In the case of articular cartilage and knee menisci, traumatic damage is common in young active people. Natural repair is often poor due to limited vascularity. If untreated, damage commonly leads to progressive degenerative changes, such as osteoarthritis, in the injured tissue and associated structures. Current solutions, include the use of artificial joints but these implants have a relatively short lifespan of 12-15 years with subsequent replacements lasting for shorter periods. This is a special problem for patients who have received an implant early in life.
  • [0009]
    There have been many options proposed for the repair of soft tissues. These generally involve synthetic materials, biological materials or a combination of the two. The former solutions have the advantages of providing a structure which is immunologically acceptable and with the mechanical integrity required of load bearing structures. However their instability in the body leads to relatively poor long term performance. Biological solutions traditionally involve autografts, allografts or xenografts, depending on their source of tissues. Each of these options has proved to be far from ideal with, for example, autografts leading to donor site morbidity and allografts and xenografts leading to graft rejection.
  • [0010]
    Other common solutions involve augmentation devices incorporating both synthetic structures and biological grafts. These devices depend on tissue ingrowth and regeneration induced by the successful transfer of stress from the synthetic material to the natural tissues. This stress transfer process would need to change with time after implantation as the tissue regenerates. Clinical reports are not generally convincing due to, for example, the inadequate initial performance of the synthetic component of the augmentation device.
  • [0011]
    Commonly used procedures for treatment of articular cartilage lesions include the Pridie technique which involves drilling or abrasion of the joint surface to release repair cells which form a fibrocartilaginous repair tissue. Other procedures involve the use of carbon fibre rods or mats associated with drilling and the use of allografts and xenografts. These techniques lead to the formation of soft fibrocartilaginous tissue which has limited long-term stability. Options for the treatment of damaged menisci currently include, surgery to remove the damaged portion of meniscus (20 years ago, before the meniscus was better understood, damaged menisci were removed completely), implantation of a plastic meniscus or using fibrin-glue to glue back the torn portion of meniscus. However, in plastic meniscal implants the use of hydrogels is often inadequate and there are problems with shear/stress forces on the implant. The use of fibrin glue is also unsatisfactory because the meniscus still contains a point of weakness and is a non-homogeneous anisotropic structure.
  • [0012]
    The relative failure of many surgical, synthetic and graft solutions has led to the growing interest in the development of cell-seeded repair systems for solving a number of clinical problems related to connective tissues such as articular cartilage, menisci and ligaments. These systems have also been called tissue-engineered repair systems. Typically autologous or allogenic cells are isolated from a tissue biopsy removed from a site remote from the injury. The cells are expanded in cell culture and seeded in a suitable 3D resorbable scaffold material, which when implanted into the defective or damaged site elicit a biological repair.
  • [0013]
    There are some reports describing in vitro and in vivo evaluation of cell-engineered systems for repair of load-bearing cartilaginous tissues. Examples of such systems have been described by Brittberg et al (New England Journal of Medicine 331 889-95 (1994)), WO 89/00413, WO 90/09769, WO 91116867, WO 90/12603, WO 95/31157 and Paige et al (Plastic and Reconstructive Surgery 97(1) 168-180 (1996)).
  • [0014]
    Brittberg et al describe a procedure in which autologous chondrocytes, expanded in culture, are transferred into the defect. This procedure does not involve a scaffold material and thus a periosteal graft is required, with associated donor site morbidity, to retain the cells within the defect. The implanted cells are denuded of matrix and therefore have no mechanical integrity on implantation. Also the technique is only suitable for lesions which do not include the sub-chondral bone.
  • [0015]
    Stone (WO 89/00413, WO 90/09769, WO 91/16867) describe prostheses for the intervertebral disc, meniscus or other similar tissue. Each prosthesis is said to include a dry, porous, volume matrix of biocompatible and bioresorbable fibres. These are described as being interspersed with glycosaminoglycan molecules, which may provide attachment sites for cross-links to the fibres. The shape of such devices can either be manufactured to replicate the outer surface contour of the biological structure which it is designed to replace, or can be manufactured to a larger-shape and trimmed down to size. For long term in vivo performance, these prostheses require the infiltration of functional fibrochondrocytes to provide a scaffold for the regenerating tissue structure. However, this prosthesis is not cell seeded and thus does not depend upon the use of seeded cells into the scaffold prior to implantation. Additionally, the nature of the mechanical interaction has not been specified.
  • [0016]
    The choice of biomaterials has to date been largely empirical based on biocompatibility and the maintenance of cell morphology and function. Additionally, the structural design of devices has been generally ignored. Materials such as collagen in various forms, poly-1-lactic acid and alginates have been employed. Most of the post implantation analysis has involved histological and biochemical analysis of repair tissue, with only a few reports assessing its mechanical integrity. The mechanical integrity of the device pre-implantation has been largely ignored. For example, Vacanti (WO 90/12603) and Kim et al (Plastic and Reconstructive Surgery 94(2) 233-237 (1994)) describe a method in which chondrocytes are seeded onto a bioresorbable polymer scaffold for transfer into a cartilaginous defect. Whilst the constructs may have a defined shape and size, the mechanical properties do not approach that of articular cartilage. The compressive modulus of articular cartilage is approximately 5-10 MPa. Problems associated with ensuring an initial even cell density and maintenance of chondrocytes phenotype are not addressed. The application of a coating to the scaffold was proposed but only to induce cell attachment. The method relies upon the synthesis of sufficient cartilaginous matrix to fill voids within the scaffold before any significant mechanical integrity is achieved.
  • [0017]
    Paige et al (Plastic and Reconstructive Surgery 97(1) 168-180 (1996)) propose the use of cells embedded in alginate alone. However, these devices are approximately one hundred times less stiff than cartilage raising questions about the mechanical functionality of the device.
  • [0018]
    WO 95/31157 relates to an anatomically specific bioresorbable device for healing of voids in soft tissues, such as in articular cartilage and the associated subchondral bone. The device is described as being an internal three-dimensional structure in fibrous form, termed the macrostructure, with voids which are partially or totally filled with a polymer gel, forming a microstructure. The gel provides a carrier material for selected chondrocytes and in conjunction with chemical mediators into the cartilage region of the device to enhance tissue regeneration. The gel phase is designed to be resorbed after 72 hours in vivo. This prosthesis, therefore, only depends upon the seeded microstructure to deliver the cells and to enable the short term transfer of cells on to the fibrous scaffold. The design does not depend upon the total filling of the voids by the microstructure. There is no consideration or mention of the physicochemical interaction of the macrostructure and the microstructure or the resulting mechanical integrity of the prosthesis at any time following implantation.
  • [0019]
    None of the aforementioned methods will produce a construct with a mechanical function which resembles that possessed by the tissues to be repaired. In addition none of the aforementioned methods address the transfer of mechanical load to cells within the device leading to mechanotransduction-induced desired cell response. It has now been discovered that an approach which considers both the mechanical and biological aspects of implants for repair of damaged load-bearing connective tissue can provide a superior device for implantation.
  • [0020]
    According to a first aspect of the present invention there is provided a biomechanical implant comprising at least two matrix components, the first matrix component having a porous macrostructure with the ability to withstand tensile or shear forces, the second matrix component being a hydrated gel which substantially fills the porous macrostructure of the first component and exerts a swelling pressure. The implant additionally comprises a population of animal cells having a differentiated phenotype or having an undifferentiated phenotype with the potential to differentiate into such cells.
  • [0021]
    The biomechanical implants according to the present invention are advantageous in that they provide a composite construct with mechanical properties under compressive loading which are greater than the sum of the compressive properties of the two components individually. In this manner, the composite construct may contribute to the restoration of the biomechanical function of the damaged tissue immediately post-implantation.
  • [0022]
    The implant may be a full or partial replacement for tissues where there is a mechanical interaction in both the loaded and unloaded states sufficient to set up an equilibrium between major matrix components, such as those with a mechanical function, where compression is the predominant type of loading. Suitable tissues for repair can include but are not limited to tissues such as cartilage, temperomandibular joint menisci, knee menisci and intervertebral discs.
  • [0023]
    The first matrix component may suitably be composed of a biodegradable or bioresorbable polymer such as collagen, gelatin, poly-L-lactic acid, poly-glycolic acid, polycaprolactone, polyhydroxybutarate, polyanhydrides and copolymers of the above. However, the specific use of non-resorbable polymeric components, or of non-polymeric resorbable components such as soluble bioglasses is not precluded. The first matrix component may preferably be composed of collagen.
  • [0024]
    The mechanical properties, antigenicity and degradation rate of the polymers comprising the first matrix component can be modified by the use of crosslinking agents such as glutaraldehyde, formaldehyde, tissue transglutaminase and acid aldehyde or by heat treatment. The polymers forming the first matrix component can be modified by alteration to the surface properties of the polymer. This can be achieved by coating with components known to influence cell attachment and differentiation such as hydroxyapatite, fibronectin, collagen, vitronectin, hyaluronan, proteoglycans, glycosaminoglycans or RGD (Arg-Gly-Asp) tripeptide cell attachment sequence. Coating may be restricted to specified regions of the first matrix component. Alternatively, attachment can be influenced by specific surface ultrastructural features such as grooves or microporosities within the range 0.1-50 μm, suitably 1-25 μm, preferably 3-10 μm.
  • [0025]
    The polymeric components forming the first matrix component preferably may possess a porous macrostructure consisting of interconnecting channels. The average size of the pores may range from 10-1000 μm, suitably 30-250 μm, preferably 50-150 μm with a total porosity ranging from 50-98%, suitably 60-95%, preferably 70-90%. The macrostructure can therefore be in the form of woven or non-woven fibres, sponges or foams, or a series of plates or sheets joined by interconnecting strands, fibres or adjoining plates. The macrostructure of the first matrix component can be non-homogeneous in terms of porosity, pore size and/or predominant polymeric fibre/plate/sheet orientation.
  • [0026]
    In biomechanical implants to replace articular cartilage, the dimensions of the first matrix component may be approximately 0.05-6 mm, suitably 0.075-4 mm, preferably 0.1-3 mm in thickness, corresponding to the thickness of articular cartilage. The other dimensions of the construct suitably may correspond to the dimensions of the defect to be repaired. The macrostructure conveniently possesses a surface zone with an orientation predominantly parallel to the surface. This zone preferably corresponds to the natural superficial zone of the cartilage, thereby representing approximately 10-20% of the total thickness of the construct in the range 0.005-1.2 mm, suitably 0.0075-0.8 mm, preferably 0.1-0.6 mm. The surface zone also preferably may possess a relatively low porosity, within the range 50-98%, suitably 60-95%, preferably 65-80% with average pore size between 10-1000 μm, suitably 30-250 μm, preferably 50-100 μm. The predominant macrostructural organisation within the remainder of the construct depth may be suitably perpendicular to the surface with a porosity between 50-98%, suitably 60-95%, preferably 75-90% and average pore size in the range 10-1000 μm, suitably 30-250 μm, preferably 50-150 μm. The lowermost zone, representing 0.05-1 mm in thickness, may be coated with a bioactive material such as hydroxyapatite to enhance integration with the underlying sub-chondral bone.
  • [0027]
    In the preferred embodiment for the replacement of the knee menisci, the overall dimensions of the first matrix component preferably correspond to the dimensions of the meniscal fragment to be replaced. The predominant orientation of the polymeric macrostructure of the first matrix component may be parallel to the surface of the construct in the outermost 100-300 μm of the construct corresponding to the superficial zone of the natural meniscus. The porosity within this region can be between 50-98%, suitably 60-95%, preferably 65-80% with pore size in the range 10-1000 μm, suitably 30-250 μm, preferably 50-100 μm. The central core of the polymeric macrostructure of the first matrix component may be predominantly radial in orientation with minor linking structures oriented at 90° to the predominant orientation. The porosity in this region may be between 50-98%, suitably 60-95%, preferably 75-90% with pore size in the range 10-500 μm, suitably 30-250 μm, preferably 50-150 μm.
  • [0028]
    The hydrated gel which forms the second matrix component may be a hydrated polymeric gel such as the hydrated gels of alginate, agarose, carrageenans, glycosaminoglycans, proteoglycans, polyethylene oxide or collagen. In many situations the hydrated gel may be alginate. Preferably, the hydrated gel is biodegradable or bioresorbable. Suitably, the second matrix component can withstand compressive loading.
  • [0029]
    Alginate is a polysaccharide, derived from brown seaweeds, composed of D-mannuronic and L-guluronic acid monosaccharide subunits. Whilst the sodium salt of alginate forms viscous solutions, alginate can form hydrated gels in the presence of divalent cations such as calcium due to cross linking through the negatively charged carboxyl groups residing on the L-guluronic acid residues. The viscosity of the uncrosslinked solutions and thereby the mechanical strength of crosslinked gels can be influenced by altering the average chain length of the alginate or by altering the proportion of D-mannuronic acid and L-guluronic acid residues within the polysaccharide. These factors may also influence the rate of resorption of the alginate.
  • [0030]
    The concentration of the hydrated gel forming the second matrix component may be heterogeneous within the macrostructure formed by the first matrix component of the implant. This can provide functionally graded mechanical properties throughout the depth of the implant.
  • [0031]
    The hydrated gel forming the second matrix component can be modified by the addition of factors, which are immobilised within the gels after cross-inking or which are contained within the hydrated fraction of the gel and are free to diffuse. These factors include collagen, hydroxyapatite, growth factors, cytokines, cell attachment factors, chemotactic factors, angiogenic factors and factors which may influence the attachment of the construct to the existing tissue such as hydroxyapatite, tissue transglutaminase and matrix degrading enzymes. The degree to which these factors are immobilised is dependent on the size and charge of the factor and the concentration and thereby pore size of the alginate gel. A particular example of this modification is the incorporation of collagen within the alginate gel in order to increase the overall collagen content of the composite device. This may be of particular importance in the preparation of devices for meniscal repair.
  • [0032]
    As discussed above, preferably both the first and second matrix components are resorbable and over a period of time can be resorbed and cleared in vivo by hydrolysis, enzymic degradation, depolymerisation and diffusion to be replaced by natural matrix components synthesised by the cells of the implant. In this manner, the original construct can be replaced by an entirely natural repair tissue with functional integrity which, due to the presence of cells and the appropriate mechanical and biochemical signals, can reach a stable equilibrium in terms of cell number, architecture and matrix turnover.
  • [0033]
    The animal cells in the implant can be autologous, allogeneic or xenogeneic with respect to the host, preferably the cells are autologous. Conveniently, the cells can be chondrocytes, fibrochondrocytes, fibroblasts, osteoblasts, or sub-populations thereof, which have a differentiated phenotype. Alternatively, precursors of the aforementioned cell types may be used which have the potential to differentiate into such cells.
  • [0034]
    The cells can be isolated from a tissue biopsy or from bone marrow, using methods common to those skilled in the art. If insufficient cell numbers are available at isolation the cells can be allowed to proliferate in tissue culture prior to seeding into the construct. During the proliferation phase the cells may be cultured as a monolayer on a tissue culture treated substrate and maintained in tissue culture medium such as Dulbeccos Modified Eagle's Medium supplemented with, for example, between 1 and 20% fetal calf serum or autologous human serum. Alternatively the cells may be cultured in serum free medium supplemented with mitogens on tissue culture plastic modified by the immobilisation of specific attachment factors. In another alternative approach, the differentiated cells may be seeded at a specified seeding density within alginate beads and cultured in tissue culture medium supplemented with serum or mitogenic growth factors. The cells may be isolated by dissolving the beads in a sodium citrate saline solution followed by collagenase digestion. These cells may be passaged subsequently by seeding and culture in alginate beads at the same seeding density as previously described. The cells may be cultured within a suitable rotating bioreactor.
  • [0035]
    The biomechanical implants of the present invention represent an improvement over the known devices of the prior art for at least the following reasons.
  • [0036]
    The interaction between the first and second matrix components can provide enhanced mechanical properties which are greater than the sum of the properties of the two components individually. In this manner, the implant mimics the physiochemical interaction within natural cartilaginous tissues.
  • [0037]
    The presence of immobilised cells within the second matrix component ensures a uniform cell density throughout the construct over an extended period of time. Cell density throughout the first matrix component can be varied by altering its porosity which permits heterogeneities in cell density to be achieved.
  • [0038]
    Contact inhibition of proliferation typically occurs for cells cultured as a monolayer and cells seeded onto a single factor scaffold such as that described in WO 90/12603 therefore reach a limiting cell number which does not fill the voids within the scaffold. Whereas the present invention allows for cells to be maintained in a 3-dimensional state which does not induce contact inhibition of proliferation to occur until the entire 3-dimensional volume is filled. In this way, a greater cell density is achieved or a lower initial seeding density may be used.
  • [0039]
    Cell morphology is known to influence cell phenotype and the type, quantity and organisation of extracellular matrix produced by the cells. The present invention permits cells to be maintained in either a rounded or elongated morphology, thereby allowing control of cell phenotype to be achieved. The meniscus contains two sub-populations of cells, one which is elongated and fibroblastic in phenotype, the other rounded and chondrocytic in phenotype. The phenotypes are interchangeable by the use of appropriate cell culture conditions. The present invention permits the restoration of the two sub-populations by seeding cells onto the first matrix component and within the second matrix component.
  • [0040]
    The biomechanical implant of the present invention also permits the transfer of mechanical load applied to the construct to the cells seeded within it in a defined manner. The inherent mechanical integrity of the construct allows mechanical load to be applied either in vitro or in vivo. Different cellular strain regimes and mechanotransduction pathways can be induced by seeding the cells onto the first matrix component or within the second matrix component.
  • [0041]
    Furthermore, it is known that mechanical strain influences cell behaviour in many load-bearing connective tissue such as articular cartilage, meniscus, tendon, ligament, intervertebral disc, bone and skin. In many cases this phenomenon can be crucial to the maintenance of tissue structure and function. The exact mechanism by which cells sense and respond to strain, known as mechanotransduction, is unclear but is believed to include cell deformation, alterations in fluid pressure, streaming potentials, fluid flow, alterations in nutrient concentration and transport, alteration in pH and variations in the osmotic environment. The preferred embodiments of the present invention may induce alterations in cell behaviour in response to mechanical loading through many of the aforementioned mechanotransduction pathways. Mechanical loading may be applied to the cells within the construct prior to implantation using specially designed technologies or applied to the cells within the construct post implantation through defined exercise regimes or through externally applied regimes such as continuous passive motion regimes. Mechanical loading regimes, applied in a static or dynamic manner may take a variety of forms including, although by no means exclusively, uniaxial compression or tension or hydrostatic pressure. Static and dynamic peak strain amplitude may be in the range between 0.5-30%, suitably 1-25%, preferably 5-20% whilst dynamic frequencies should range from 0.001-10 Hz, suitably 0.01-5 Hz, preferably 0.1-3 Hz.
  • [0042]
    The are also several advantages in the application of mechanical strain which may be transferred to the cells within the construct prior to implantation.
  • [0043]
    Firstly, the use of optimal strain windows of biosynthetic response can quantitatively increase metabolic parameters known to influence the success of tissue engineered repair devices such as cell proliferation, proteoglycan synthesis and collagen synthesis.
  • [0044]
    Secondly, qualitative reorganisation and/or orientation of newly synthesised matrix components in response to strain may be induced which can provide anisotropy and, potentially, improved gross mechanical properties. Orientation of cells along strain fields may induce long-term production of oriented matrix. Oriented cell proliferation may also restore the cell architecture, such as columns which are a feature of articular cartilage and are important in the structural/functional relationship within the tissue. The cells in the implant may suitably possess a pre-implantation strain history and can therefore be adapted to respond to mechanical strain post-implantation.
  • [0045]
    According to a second aspect of the present invention there is provided a method of repairing damaged connective tissue, in which the method comprises the step of wholly or partially replacing the damaged tissue with a biomechanical implant as defined above.
  • [0046]
    This aspect of the present invention also contemplates the use of at least two matrix components the first matrix component having a porous macrostructure with the ability to withstand tensile or shear forces, the second matrix component being a hydrated gel which substantially fills the porous macrostructure of the first component and has the ability to withstand compressive loading, and a population of animal cells having a differentiated phenotype or having an undifferentiated phenotype with the potential to differentiate into such cells, in the preparation of a biomechanical implant for repair of damaged connective tissue.
  • [0047]
    The implant may be most applicable to tissues where there is a mechanical interaction in the loaded and unloaded state sufficient to set up an equilibrium between major matrix components, such as those with a mechanical function, where compression is the predominant type of loading. Suitable tissues for repair can include but are not limited to tissues such as cartilage, temperomandibular joint menisci, knee menisci and intervertebral discs.
  • [0048]
    According to a third aspect of the present invention, there is provided a biomechanical implant comprising at least two matrix components the first matrix component having a porous macrostructure with the ability to withstand tensile or shear forces, the second matrix component being a hydrated gel which substantially fills the porous macrostructure of the first component and has the ability to withstand compressive loading, the implant additionally comprising a population of animal cells having a differentiated phenotype or having an undifferentiated phenotype with the potential to differentiate into such cells, as a combined preparation for simultaneous, separate or sequential use in the preparation of a biomechanical implant for repair of damaged connective tissue.
  • [0049]
    According to a fourth aspect of the present invention, there is provided a method for the manufacture of a biomechanical implant a s defined above, in which the method comprises the steps of:
  • [0050]
    (a) infiltrating a solution of the uncrosslinked precursor of the hydrated gel into the first matrix component,
  • [0051]
    (b) crosslinking the gel in situ to form the second matrix component,
  • [0052]
    (c) incorporating the cells into the matrix, and
  • [0053]
    (d) applying mechanical loading.
  • [0054]
    Where the hydrated gel is alginate, a solution of sodium alginate at concentrations ranging from 0.5-10% (w/v), suitably, 1-8% (w/v), preferably 2-6% (w/v) may be prepared in water, salt solution or tissue culture medium. The solution can be infiltrated into the porosity of the first matrix component by diffusion, vacuum infiltration or centrifugation in a manner to ensure that all the pores are filled. Sodium alginate solutions swell, markedly, when separated from an isotonic saline solution by a permeable barrier. Typically, a 50% increase in weight occurs during the first 4 hours of water uptake. In this manner sodium alginate entrapped within the first matrix component can be immersed in saline and will exert a physicochemical swelling pressure which is resisted by the first matrix component thereby setting up tensile forces within the first matrix component in the unloaded state. This relies upon the ability of the first matrix component to resist swelling and not exhibit marked swelling in its own right. This ability is determined by the structural composition of the first matrix component.
  • [0055]
    The composite construct can then be immersed in a solution containing a salt of a divalent cation to induce crosslinkage of the alginate in situ to form a hydrated gel. The most preferred crosslinking solution contains calcium chloride at concentrations ranging from 10-500 mM, suitably 25-250 mM, preferably 50-150 mM. In this manner the alginate gel can be immobilised within the porosity of the first matrix component.
  • [0056]
    The cells can be incorporated into the construct in a number of ways, which include direct attachment to the first matrix component, addition of the cells to the solution of the second matrix component prior to infiltration into the first matrix component or attachment of the cells to the first matrix component and immobilisation of cells within the second matrix component to produce two sub-populations of cells within the construct with different morphologies.
  • [0057]
    Direct attachment of the cells to the first matrix component can be achieved by the addition of a suspension of cells in medium to a suitably prepared piece of the first matrix component. Infiltration of the cell suspension into the porosity of the first matrix component can draw cells into it which subsequently attach and spread on the polymeric surface of the first matrix component. The cells may assume a flattened or elongated morphology. Subsequent culture in suitable tissue culture medium may cause proliferation and migration of the cells which can lead to the formation of a uniform covering of cells over the entire surface of the first matrix component. At any stage after the cells have attached to the first matrix component, infiltration and crosslinking of the second matrix component can be performed.
  • [0058]
    Addition of the cells to the solution of the second matrix component prior to infiltration into the first matrix component achieves incorporation of the cells into the matrix as the infiltration draws the cells into the porous structure of the first matrix component in association with the second matrix component. The cells can become immobilised within the hydrated gel after crosslinking of the second matrix component. Thereby the cells may retain a rounded morphology and remain unattached directly to the first matrix component.
  • [0059]
    Attachment of a proportion of cells to the first matrix component and immobilisation of cells within the second matrix component can produce two sub-populations of cells within the construct with different morphologies. Alternatively, expanded sub-populations of cells, such as cells isolated from the superficial and deep zones of articular cartilage, may be seeded in either or both matrix components within the distinct zones of the implant. The construct can be implanted directly after cell seeding or the construct containing cells can be maintained in tissue culture to allow the synthesis of extracellular matrix components by the cells and proliferation of the cells prior to implantation. Defined loading regimes can be applied to the cells within the construct during the culture phase using specially designed technologies as described in the examples.
  • [0060]
    Preferred features and characteristics of the second and subsequent aspects are as for the first aspect mutatis mutandis.
  • [0061]
    The invention will now be described by way of example with reference to the accompanying Examples and drawings which are provided for the purposes of illustration and neither of which are to be construed as being limiting on the present invention. In the following description, reference is made to a number of drawings, in which:
  • [0062]
    [0062]FIG. 1 shows a photomicrograph of a haematoxylin and eosin stained section prepared from a meniscal fibrochondrocyte seeded collagen gel fixed immediately after casting. Magnification ×250.
  • [0063]
    [0063]FIG. 2 shows a photornicrograph of a haematoxylin and eosin stained section prepared from a collagen sponge construct seeded with bovine chondrocytes and cultured for 14 days. Magnification ×250.
  • [0064]
    [0064]FIG. 3 shows a photomicrograph of a haematoxylin and eosin stained section prepared from a bovine chondrocyte seeded alginate construct which had been cultured for 7 days. Magnification ×250.
  • [0065]
    [0065]FIG. 4 shows a photomicrograph of a haematoxylin and eosin stained section prepared from a bovine chondrocyte seeded agarose construct which had been cultured for 3 days. Magnification ×250.
  • [0066]
    [0066]FIG. 5 shows a photomicrograph of a haematoxylin and eosin stained section prepared from a collagen gel/alginate composite construct seeded with meniscal fibrochondrocytes which had been cultured for 3 days. Magnification ×500.
  • [0067]
    [0067]FIG. 6 shows a photomicrograph of a haematoxylin and eosin stained section prepared from a collagen sponge/alginate composite construct seeded with chondrocytes which had been cultured for 1 day. Magnification ×250.
  • [0068]
    [0068]FIG. 7 shows a photornicrograph of a haematoxylin and eosin stained section prepared from a collagen sponge/agarose composite construct seeded with chondrocytes which had been cultured for 7 days. Magnification ×250.
  • [0069]
    [0069]FIG. 8a shows a graph representing glycosaminoglycan synthesis by chondrocytes seeded in agarose constructs and subjected to 15% gross compressive strain at various frequencies for 48 hr. The values have been normalised to unstrained control levels (100%).
  • [0070]
    [0070]FIG. 8b shows a graph representing [3H]-thymidine incorporation by chondrocytes seeded in agarose constructs and subjected to 15% gross compressive strain at various frequencies for 48 hr. The values have been normalised to unstrained control levels (100%).
  • [0071]
    [0071]FIG. 9 shows a graph representing [3H]-thymidine incorporation by chondrocytes isolated from the superficial and deep zones of cartilage and seeded in agarose constructs and subjected to 15% gross compressive strain at various frequencies for 48 hours. The values have been normalised to unstrained control levels (100%).
  • EXAMPLE (1) Cell Isolation and Expansion in Culture
  • [0072]
    Chondrocytes were isolated from either bovine cartilage or human cartilage obtained after amputation due to osteosarcoma. Meniscal cells were isolated from human knee menisci obtained after amputation due to osteosarcoma. The cartilage or meniscal tissue was cut into cubes of no more than 2 mm3 and sequentially digested with 1% (w/v) pronase (BDH Ltd. Poole, England) in Dulbecco's Modified Eagles Medium, 2% HEPES buffer, 1% Glutamine and 1% pencillin/streptomycin (referred hereafter as DMEM) containing 20% FCS for 1 h at 37° C. followed by collagenase Type 1A (Sigma) in DMEM +20% FCS for 2 h at 37° C. The enzyme concentration (i.u./ml) is optimised for each new batch of collagenase. Debris was removed from the cell containing medium by filtration through a nylon sieve (Falcon 70 μm pore size) and the cells separated by centrifugation at 1000 g for 5 minutes. The cell pellet was washed ×2 with DMEM+20% FCS and resuspended in an appropriate volume of medium. Cell density and viability was determined by the Trypan Blue exclusion test.
  • [0073]
    Where necessary, the cell population will be expanded to the desired number by repeat passage. Cells will be cultured as a monolayer in tissue culture flasks in DMEM+10% FCS at 37° C./5%CO2 with medium changes every two days. At confluence the cells will be lifted with 0.2% trypsin/EDTA and divided into three flasks for further culture.
  • EXAMPLE (2) Seeding of Fibrochondrocytes into Collagen Gels
  • [0074]
    Human fibrochondrocyte seeded collagen gels were prepared by mixing 12 ml of double strength Dulbeccos Modified Eagle Medium (DMEM, Gibco, Paisley, UK), 3 ml of a cell suspension (1×106 cell/ml in DMEM), 3 ml foetal calf serum (FCS, Gibco, Paisley, UK), 3 ml 0.1 M NaOH and 9 ml collagen solution (3 mg/ml collagen type I in 0.5M acetic acid, ICN, Paisley, UK). All components were maintained at 4° C. during mixing. Aliquots (1.5 ml) of the solution were added to wells and gelled at 37° C./5%CO2 for 30 minutes. The gels were maintained at 37° C./5%CO2 in DMEM+ 10% FCS+150 μg/ml ascorbate with medium changes every 2 days. Cell-induced contraction of the gel occurred during the first 3 days. Histology revealed the presence of cells with typical fibroblastic morphology evenly distributed within a disorganised fibrous collagen matrix, as shown in FIG. 1.
  • EXAMPLE (3) Seeding of Chondrocytes onto Collagen Sponges
  • [0075]
    Bovine chondrocytes were seeded onto collagen sponges by absorption. Cylinders of absorbable sponge 3 mm thick and 6 mm in diameter (Helistat® Colla-Tec, Inc. USA) were cut. Medium (100 μl) containing 1.5×107 cells/ml was either added dropwise to the surface of the dry matrix or the sponge was immersed in cell containing medium. The sponges containing cells were cultured in DMEM+20% FCS for up to 24 days with medium changes every two days. Histology using haematoxylin and eosin staining revealed the presence of clusters of chondrocytes within the sponge matrix. The majority of cells exhibited rounded morphology although a proportion were flattened or fibroblastic in appearance as shown in FIG. 2. The density was not homogeneous with the greatest proportion of cells at the periphery of the sponge. Evidence of synthesis of proteoglycan rich matrix around the cells was noted.
  • EXAMPLE (4) Seeding of Chondrocytes in Alginate
  • [0076]
    An equal volume of 4% (w/v) alginate (Kelco International Ltd. Waterfield, Tadworth, Surrey, UK) in Earle's buffered salt solution (EBSS) was mixed with 1.6×107 cells/ml in DMEM containing 20% FCS by gentle agitation. Cross-linking of the alginate suspension was effected by dialysis against a solution of 100 mM CaCl2 in DMEM/10% FCS. The crosslinked gel constructs were cultured in DMEM+20% FCS+ 150 μg/ml ascorbate for up to 24 days with medium changes every 2 days. After 6 days in culture a proportion of the chondrocytes within the alginate gel had undergone proliferation to form small clusters as shown in FIG. 3. The cells retained their original rounded morphology and synthesised a ‘halo’ of cartilaginous matrix.
  • EXAMPLE (5) Seeding of Chondrocytes into Agarose
  • [0077]
    During preparation of a cell suspension containing 2×107 cells/ml, a 6% suspension of agarose (type VII, Sigma, Poole, England) in distilled water was melted by autoclaving and subsequently cooled to 37° C. The chondrocyte suspension was added to an equal volume of agarose to give a final concentration of 1×107 cells/ml in 3% agarose. The agarose suspension was plated in a tissue culture dish and gelled at 4° C. for 20 minutes. Cylindrical constructs, 5 mm diameter×5 mm height were formed and cultured in DMEM+20% FCS+150 μg/ml ascorbate for up to 24 days. Histology using haematoxylin and Safranin-O staining revealed the presence of an even distribution of cells with a rounded morphology as shown in FIG. 4. After 3 days a significant ‘halo’ of cartilaginous matrix was present around the cells and cell clusters formed by proliferation were noted after 6 days.
  • EXAMPLE (6) Preparation of Two Component Constructs by Diffusion Techniques
  • [0078]
    Fibrochondrocyte seeded collagen gels were cast as described in example 2 and cultured for 24 hr. The gels were placed in a suspension of 2% (w/v) alginate in DMEM+10% FCS:EBSS (1:1). The alginate was crosslinked by dialysis against a solution of 100 mM CaCl2 in DMEM/10% FCS. The constructs were cultured in DMEM+10% FCS +150 μg/ml ascorbate for up to 24 days with medium changes every 2 days. Histology revealed the presence of evenly distributed cells with a fibroblastic morphology throughout the composite as shown in FIG. 5. Alginate content was inhomogeneous with greater concentration at the periphery of the construct.
  • [0079]
    Collagen sponges with or without prior culture were infiltrated with 2.0% (w/v) alginate containing 1.5×107 chondrocytes/ml in DMEM+20% FCS:EBSS (1:1) or 2% (w/v) agarose type VII containing 4×106 cells/ml in DMEM+20% FCS:EBSS (1:1) by dropwise addition to the surface of the sponge. The alginate was crosslinked by bathing the construct in a solution of 100 mM CaCl2 in DMEM/10% FCS. Agarose containing constructs were gelled by incubation at 4° C. for 30 minutes. The constructs were cultured in DMEM+20% FCS+150 μg/ml ascorbate for up to 24 days with medium changes every 2 days. Cells, associated with the agarose were found evenly distributed within the porous microstructure of the collagen sponge and exhibited rounded morphology as shown in FIG. 6. There was evidence of cartilaginous matrix production around the cells.
  • EXAMPLE (7) Preparation of Two Component Constructs by Vacuum Infiltration
  • [0080]
    Collagen gels or sponges 6 mm diameter with or without prior culture of cells were placed in a 96 well sterile vacuum manifold plate (Multiscreen® Millipore UK), 100 μl of 2% (w/v) alginate in DMEM+10% FCS:EBSS (1:1) containing 1.5×107 cells/ml was layered on top of the collagen gel or sponge. A gentle vacuum was applied to incorporate the alginate and cells into the collagen gel or sponge. Crosslinking of the alginate was effected by bating the construct in a solution of 100 mM CaCl2 in DMEM/10% FCS. An even distribution of cells was seen throughout the porous microstructure of the collagen sponge. The cells were associated with the alginate which was also evenly distributed and the cells possessed a rounded morphology as shown in FIG. 7.
  • EXAMPLE (8) Preparation of Two Component Constructs by Low Speed Centrifugation
  • [0081]
    Collagen gels or sponges with or without prior culture of cells were placed in wells of a tissue culture plate. 2% alginate in Earle's buffered salt solution (EBSS) containing 4× 106 cells/ml in DMEM and 10% FCS was gently layered on top of the collagen gel or sponge. The tissue culture plate was centrifuged at 100 g for 5 minutes to incorporate the alginate and cell suspension within the collagen gel or sponge. Crosslinking of the alginate was effected by bathing the construct in a solution of 100 mM CaCl2 in DMEM/10% FCS.
  • EXAMPLE (9) Mechanical Testing of Two Component Constructs and Their Components
  • [0082]
    The mechanical characteristics of the collagen gels and composites were evaluated. Uniformly sized cores of each material to be tested were mounted between two large plattens and tested to failure in compression at a crosshead speed of 1 mm/min using a universal testing machine (Instron Model 1122). The tangent modulus, an estimate of the material stiffness, was calculated from the linear region using the following equation: modulus ( MPa ) = Ft dt A
  • [0083]
    Where F=compressive force; t=Original thickness of material; dt=change in thickness; A=sample cross-sectional area. Another parameter, the equilibrium modulus, is calculated from a load relaxation experiment conducted at a prescribed strain of 20%.
  • [0084]
    Composite constructs consisting of 2% Keltone HV alginate infiltrated by vacuum into collagen sponges had a significantly greater tangent modulus than either collagen or alginate alone, indicating physicochemical interaction between the components as shown in Table 1.
    TABLE 1
    Mechanical evaluation of single
    and two component collagen and alginate constructs.
    Tangent Equilibrium
    Construct Modulus Modulus
    Collagen 85 kPa 32 kPa
    sponge/alginate
    construct
    Collagen sponge <1 kPa <1 kPa
    construct
    Alginate 25 kPa 9 kPa
    construct.
  • EXAMPLE (10) Mechanical Stimulation of Cells in Hydrated Gels
  • [0085]
    A specially designed cell straining apparatus (Dartec Ltd, Stourbridge, UK) described in the literature was used to apply compressive strain to chondrocytes seeded in agarose as described in example 6 (Lee, D. A., and Bader, D. L., Journal of Orthopaedic Research 15 (2) 181-188 (1997). The constructs were subjected to a compressive strain amplitude of 15% at three dynamic frequencies (0.3 Hz, 1 Hz, 3 Hz). In addition static compressive strain was applied. Controls were unstrained. The compressive strain was applied for 48 hr and GAG synthesis, cell proliferation and total protein synthesis in response to strain were assessed. GAG synthesis was stimulated at 1 Hz as shown in FIG. 8a, whilst cell proliferation was stimulated by all of the dynamic strain regimes as shown in FIG. 8b.
  • EXAMPLE (11) Mechanical Stimulation of Chondrocyte Sub-populations in Hydrated Gels
  • [0086]
    Chondrocytes were isolated, separately, from the superficial and deep zones of bovine cartilage and seeded within 3 % agarose constructs. The constructs were subjected to a compressive strain amplitude of 15% at three dynamic frequencies (0.3 Hz, 1 Hz, 3 Hz). In addition, static compressive strain was applied. Controls were unstrained. The compressive strain was applied for 48 hours and cell proliferation in response to strain was assessed. Cell proliferation was stimulated in superficial zone cells by all of the dynamic strain regimes as shown in FIG. 9. By contrast, deep zone cells were unaffected by both static and dynamic strain regimes as shown in FIG. 9.

Claims (27)

1. A biomechanical implant comprising at least two matrix components, the first matrix component having a porous macrostructure with the ability to withstand tensile or shear forces, the second matrix component being a hydrated gel which substantially fills the porous macrostructure of the first component and exerts a swelling pressure, the implant additionally comprising a population of animal cells having a differentiated biomechanical phenotype or having an undifferentiated phenotype with the potential to differentiate into such cells.
2. A biomechanical implant as claimed in
claim 1
, in which the implant is a full or partial replacement for a tissue where there is a mechanical interaction in both the loaded and unloaded states sufficient to set up an equilibrium between major matrix components.
3. A biomechanical implant as claimed in
claim 2
, in which the tissue comprises cartilage, temperomandibular joint meniscus, knee meniscus or an intervertebral disc.
4. A biomechanical implant as claimed in any one of
claims 1
to
3
, in which the first matrix component is composed of a biodegradable or bioresorbable polymer.
5. A biomechanical implant as claimed in
claim 4
, in which the biodegradable or bioresorbable polymer comprises collagen, gelatin, poly-L-lactic acid, poly-glycolic acid, polycaprolactone, polyhydroxybutarate, polyanhydrides or a copolymer thereof
6. A biomechanical implant as claimed in
claim 4
or
claim 5
, in which the biodegradable or bioresorbable polymer is modified by crosslinking agents.
7. A biomechanical implant as claimed in any one of
claims 4
to
6
, in which the first matrix component further comprises a coating of hydroxyapatite, fibronectin, collagen, vitronectin, hyaluronan, proteoglycans, glycosaminoglycans or RGD (Arg-Gly-Asp).
8. A biomechanical implant as claimed in any one of
claims 4
to
7
, in which the coating is restricted to specified portions of the implant.
9. A biomechanical implant as claimed in any one of
claims 4
to
8
, in which the first matrix component has a groove or microporosities in the range 0.1-50 μm, suitably 1-25 μm, preferably 3-10 μm.
10. A biomechanical implant as claimed in any one of
claims 4
to
9
, in which the polymeric components forming the first matrix component have an average pore size ranging from 10-1000 μm, suitably 30-250 μm, preferably 50-150 μm with a total porosity ranging from 50-98%, suitably 60-95%, preferably 70-90%.
11. A biomechanical implant as claimed in any one of
claims 1
to
10
which is in the form of woven or non-woven fibres, sponges, foams, or a series of plates or sheets joined by interconnecting strands, fibres or adjoining plates.
12. A biomechanical implant as claimed in any one of
claims 1
to
11
, in which the hydrated gel which forms the second matrix component is a hydrated polymeric gel.
13. A biomechanical implant as claimed in any one of
claims 1
to
12
, in which the hydrated polymeric gel is biodegradable or bioresorbable.
14. A biomechanical implant as claimed in
claim 12
or
claim 13
, in which the hydrated polymeric gel comprises alginate, agarose, carrageenans, glycosaminoglycans, proteoglycans, polyethylene oxide or collagen monomers.
15. A biomechanical implant as claimed in any one of
claims 12
to
14
, in which the hydrated gel is heterogeneous in nature.
16. A biomechanical implant as claimed in any one of
claims 12
to
15
, in which the hydrated gel is cross-linked.
17. A biomechanical implant as claimed in any one of
claims 12
to
16
, in which the hydrated gel further comprises collagen, hydroxyapatite, growth factors, cytokines, cell attachment factors, chemotactic factors, angiogenic factors or enzymes.
18. A biomechanical implant as claimed in any one of
claims 1
to
17
, in which the animal cells in the implant are autologous, allogeneic or xenogeneic with respect to the host.
19. A biomechanical implant as claimed in
claim 18
, in which the cells comprise chondrocytes, fibrochondrocytes, fibroblasts or osteoblasts, or sub-populations thereof, or precursors thereof.
20. A biomechanical implant as claimed in
claim 18
or
claim 19
, in which the cells are derived from a tissue biopsy.
21. A method of repairing damaged connective tissue, in which the method comprises the step of wholly or partially replacing the damaged tissue with a biomechanical implant as defined in any of
claims 1
to
20
.
22. The use of at least two matrix components, the first matrix component having a porous macrostructure with the ability to withstand tensile or shear forces, the second matrix component being a hydrated gel which substantially fills the porous macrostructure of the first component and has the ability to withstand compressive loading, and a population of animal cells having a differentiated biomechanical phenotype or having an undifferentiated phenotype with the potential to differentiate into such cells, in the preparation of a biomechanical implant for repair of damaged connective tissue.
23. The use as claimed in
claim 22
, in which the tissue to be repaired is cartilage, temperomandibular joint menisci, knee menisci or intervertebral discs.
24. A biomechanical implant comprising at least two matrix components the first matrix component having a porous macrostructure with the ability to withstand tensile or shear forces, the second matrix component being a hydrated gel which substantially fills the porous macrostructure of the first component and has the ability to withstand compressive loading, the implant additionally comprising a population of animal cells having a differentiated biomechanical phenotype or having an undifferentiated phenotype with the potential to differentiate into such cells, as a combined preparation for simultaneous, separate or sequential use in the preparation of a biomechanical implant for repair of damaged connective tissue.
25. A method for the manufacture of a biomechanical implant as defined in any one of
claims 1
to
20
, in which the method comprises the steps of:
(a) infiltrating a solution of the uncrosslinked precursors of the hydrated gel into the first matrix component,
(b) crosslinking the gel in situ to form the second matrix component,
(c) incorporating the cells into the matrix, and
(d) applying a mechanical loading.
26. A method as claimed in
claim 25
, in which the uncrosslinked precursors of the hydrated gel are infiltrated into the first matrix component by diffusion, vacuum infiltration or centrifugation.
27. A method as claimed in
claim 25
or
claim 26
, in which the cells are incorporated into the matrix (i) by direct attachment to the first matrix component, (ii) by addition of the cells to the solution of the second matrix component prior to infiltration into the first matrix component, or (iii) by attachment of the cells to the first matrix component and immobilisation of cells within the second matrix component.
US09770620 1997-03-07 2001-01-29 Tissue implant Abandoned US20010016772A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB9704749A GB9704749D0 (en) 1997-03-07 1997-03-07 Tissue Implant
GB9704749.2 1997-03-07
PCT/GB1998/000673 WO1998040111A1 (en) 1997-03-07 1998-03-06 Tissue implant
US09188165 US6306169B1 (en) 1997-03-07 1998-11-09 Tissue implant
US09770620 US20010016772A1 (en) 1997-03-07 2001-01-29 Tissue implant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09770620 US20010016772A1 (en) 1997-03-07 2001-01-29 Tissue implant

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09188165 Continuation US6306169B1 (en) 1997-03-07 1998-11-09 Tissue implant

Publications (1)

Publication Number Publication Date
US20010016772A1 true true US20010016772A1 (en) 2001-08-23

Family

ID=10808861

Family Applications (2)

Application Number Title Priority Date Filing Date
US09188165 Expired - Fee Related US6306169B1 (en) 1997-03-07 1998-11-09 Tissue implant
US09770620 Abandoned US20010016772A1 (en) 1997-03-07 2001-01-29 Tissue implant

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09188165 Expired - Fee Related US6306169B1 (en) 1997-03-07 1998-11-09 Tissue implant

Country Status (5)

Country Link
US (2) US6306169B1 (en)
JP (1) JP2001514551A (en)
EP (1) EP1019109A1 (en)
GB (1) GB9704749D0 (en)
WO (1) WO1998040111A1 (en)

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1338291A2 (en) * 2002-02-21 2003-08-27 Ed. Geistlich Söhne Ag Für Chemische Industrie Resorbable extracellular matrix for reconstruction of bone
US20030220691A1 (en) * 2002-05-23 2003-11-27 Pioneer Laboratories, Inc. Artificial intervertebral disc device
US20040063200A1 (en) * 2000-07-28 2004-04-01 Elliot Chaikof Biological component comprising artificial membrane
US20040133275A1 (en) * 2000-03-27 2004-07-08 Mansmann Kevin A. Implants for replacing cartilage, with negatively-charged hydrogel surfaces and flexible matrix reinforcement
US20040228901A1 (en) * 2002-09-18 2004-11-18 Trieu Hai H. Collagen-based materials and methods for treating synovial joints
US20050038520A1 (en) * 2003-08-11 2005-02-17 Francois Binette Method and apparatus for resurfacing an articular surface
US20050125077A1 (en) * 2003-12-05 2005-06-09 Harmon Alexander M. Viable tissue repair implants and methods of use
US20050186673A1 (en) * 1995-02-22 2005-08-25 Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie Collagen carrier of therapeutic genetic material, and method
US20050186283A1 (en) * 1997-10-10 2005-08-25 Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie Collagen carrier of therapeutic genetic material, and method
WO2005082333A1 (en) * 2004-02-26 2005-09-09 Bausch & Lomb Incorporated Alginate viscoelastic composition, method of use and package
US20060159668A1 (en) * 1997-10-10 2006-07-20 Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie Resorbable extracellular matrix for reconstruction of bone
US20060200245A1 (en) * 2005-03-07 2006-09-07 Sdgi Holdings, Inc. Materials, devices, and methods for in-situ formation of composite intervertebral implants
US20060263335A1 (en) * 2003-03-27 2006-11-23 Regentec Ltd. Porous matrix
WO2006136905A2 (en) * 2005-06-20 2006-12-28 Giuseppe Calvosa Biocompatible composition for replacing/regenerating tissues
US20070031388A1 (en) * 1997-10-10 2007-02-08 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Cell-charged multi-layer collagen membrane
US20070134343A1 (en) * 2002-11-15 2007-06-14 Trieu Hai H Collagen-based materials and methods for treating synovial joints
US20070156174A1 (en) * 2006-01-03 2007-07-05 Arthrotek, Inc. Method and apparatus for repairing a meniscus
US20080004431A1 (en) * 2006-06-30 2008-01-03 Warsaw Orthopedic Inc Method of manufacturing an injectable collagen material
US20080004703A1 (en) * 2006-06-30 2008-01-03 Warsaw Orthopedic, Inc. Method of treating a patient using a collagen material
US20080071385A1 (en) * 2003-11-26 2008-03-20 Depuy Mitek, Inc. Conformable tissue repair implant capable of injection delivery
US20080152687A1 (en) * 2006-12-21 2008-06-26 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
WO2007057908A3 (en) * 2005-11-21 2009-04-09 Alexander Dubson Spinal nucleus prosthesis device
US20090259312A1 (en) * 2008-04-09 2009-10-15 Active Implants Corporation Meniscus Prosthetic Devices with Anti-Migration Features
US20090259313A1 (en) * 2008-04-09 2009-10-15 Active Implants Corporation Manufacturing and material processing for prosthetic devices
US20090306687A1 (en) * 2005-10-31 2009-12-10 Life Spring Biotech Co., Ltd. Scleral buckling band and method for making the same
US20100040667A1 (en) * 2006-09-07 2010-02-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treating bone cancer
US7744651B2 (en) 2002-09-18 2010-06-29 Warsaw Orthopedic, Inc Compositions and methods for treating intervertebral discs with collagen-based materials
US20100196440A1 (en) * 2006-10-23 2010-08-05 Eth Zurich Implant Material
US7824701B2 (en) 2002-10-18 2010-11-02 Ethicon, Inc. Biocompatible scaffold for ligament or tendon repair
US20110004305A1 (en) * 2009-07-06 2011-01-06 Aesculap Ag Elevated implant for the reconstruction of meniscus defects or partial meniscus defects
US7991599B2 (en) 2008-04-09 2011-08-02 Active Implants Corporation Meniscus prosthetic device selection and implantation methods
US8016867B2 (en) 1999-07-23 2011-09-13 Depuy Mitek, Inc. Graft fixation device and method
US8016884B2 (en) 2008-04-09 2011-09-13 Active Implants Corporation Tensioned meniscus prosthetic devices and associated methods
US20110262541A1 (en) * 2010-04-23 2011-10-27 Osteotech, Inc. Foam-formed collagen strand
US8118779B2 (en) 2006-06-30 2012-02-21 Warsaw Orthopedic, Inc. Collagen delivery device
US8137686B2 (en) 2004-04-20 2012-03-20 Depuy Mitek, Inc. Nonwoven tissue scaffold
US8192491B2 (en) 2006-10-09 2012-06-05 Active Implants Corporation Meniscus prosthetic device
US8221780B2 (en) 2004-04-20 2012-07-17 Depuy Mitek, Inc. Nonwoven tissue scaffold
US8226715B2 (en) 2003-06-30 2012-07-24 Depuy Mitek, Inc. Scaffold for connective tissue repair
US8241360B2 (en) 2002-05-23 2012-08-14 Pioneer Surgical Technology, Inc. Artificial disc device
US8399619B2 (en) 2006-06-30 2013-03-19 Warsaw Orthopedic, Inc. Injectable collagen material
US20130110245A1 (en) * 2010-03-30 2013-05-02 3T Textiltechnologietransfer Gmbh Implant having a sandwich structure, implant system and implant support
US8449561B2 (en) 1999-07-23 2013-05-28 Depuy Mitek, Llc Graft fixation device combination
US8613938B2 (en) 2010-11-15 2013-12-24 Zimmer Orthobiologics, Inc. Bone void fillers
WO2014011891A1 (en) * 2012-07-11 2014-01-16 Osiris Therapeutics, Inc. Methods of manufacturing cartilage products
US8690874B2 (en) 2000-12-22 2014-04-08 Zimmer Orthobiologics, Inc. Composition and process for bone growth and repair
US8691259B2 (en) 2000-12-21 2014-04-08 Depuy Mitek, Llc Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
US9233011B2 (en) 2006-09-15 2016-01-12 Pioneer Surgical Technology, Inc. Systems and apparatuses for inserting an implant in intervertebral space
US9241807B2 (en) 2011-12-23 2016-01-26 Pioneer Surgical Technology, Inc. Systems and methods for inserting a spinal device
US9445916B2 (en) 2003-10-22 2016-09-20 Pioneer Surgical Technology, Inc. Joint arthroplasty devices having articulating members
US9511171B2 (en) 2002-10-18 2016-12-06 Depuy Mitek, Llc Biocompatible scaffolds with tissue fragments
US9655730B2 (en) 2006-10-09 2017-05-23 Active Implants LLC Meniscus prosthetic device

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635390B1 (en) 2000-01-14 2009-12-22 Marctec, Llc Joint replacement component having a modular articulating surface
US7959635B1 (en) 2000-01-14 2011-06-14 Marctec, Llc. Limited incision total joint replacement methods
US6770078B2 (en) * 2000-01-14 2004-08-03 Peter M. Bonutti Movable knee implant and methods therefor
US8795242B2 (en) 1994-05-13 2014-08-05 Kensey Nash Corporation Resorbable polymeric device for localized drug delivery
US7963997B2 (en) * 2002-07-19 2011-06-21 Kensey Nash Corporation Device for regeneration of articular cartilage and other tissue
DE69724780D1 (en) * 1996-05-22 2003-10-16 Univ Ben Gurion Polysaccharide sponges for cell culture and transplantation
US6551355B1 (en) * 1998-08-14 2003-04-22 Cambridge Scientific, Inc. Tissue transplant coated with biocompatible biodegradable polymer
DE19922078A1 (en) * 1999-05-15 2000-11-23 Weitzel Kage Doris Tissue construct for transplantation surgery
DE19956503A1 (en) * 1999-11-24 2001-06-21 Universitaetsklinikum Freiburg Injectable bone substitute material
DE60033055D1 (en) * 1999-12-06 2007-03-08 Warsaw Orthopedic Inc Intervertebral disc treatment device
US7708741B1 (en) 2001-08-28 2010-05-04 Marctec, Llc Method of preparing bones for knee replacement surgery
WO2001054735A3 (en) * 2000-01-28 2001-12-20 Hanne Bentz Gel-infused sponges for tissue repair and augmentation
US6592566B2 (en) * 2000-02-03 2003-07-15 Arizona Board Of Regents Method for forming an endovascular occlusion
US6629997B2 (en) * 2000-03-27 2003-10-07 Kevin A. Mansmann Meniscus-type implant with hydrogel surface reinforced by three-dimensional mesh
DE60128933T2 (en) 2000-09-18 2008-02-14 Organogenesis, Inc., Canton A method for treating a patient with a cultured connective tissue construct
EP1832300A3 (en) * 2000-09-18 2008-02-27 Organogenesis Inc. Method for treating a patient using a cultured connective tissue construct
US6528052B1 (en) * 2000-09-29 2003-03-04 The Board Of Trustees Of The Leland Stanford Junior University Method for in vivo ex vivo and in vitro repair and regeneration of cartilage and collagen and bone remodeling
JP2002233567A (en) * 2000-12-06 2002-08-20 Japan Science & Technology Corp Tissue equivalent for transplantation and its method of manufacture
FR2819814B1 (en) * 2001-01-22 2004-10-29 Tbf Lab biocompatible and gellable implantable composition
US7449180B2 (en) * 2001-02-06 2008-11-11 John Kisiday Macroscopic scaffold containing amphiphilic peptides encapsulating cells
US20040151705A1 (en) * 2002-03-22 2004-08-05 Shuichi Mizuno Neo-cartilage constructs and a method for preparation thereof
JP3646162B2 (en) * 2001-07-04 2005-05-11 独立行政法人産業技術総合研究所 Play for transplantation of cartilage tissue
CA2460539C (en) 2001-09-15 2013-10-29 Rush-Presbyterian-St. Luke's Medical Center Stratified cartilage tissue and methods to engineer same
JP2003126125A (en) * 2001-10-24 2003-05-07 Katsuko Sakai Artificial blood vessel and method of preparing it
US7494664B2 (en) 2001-10-25 2009-02-24 Japan Science And Technology Agency Composite biomaterials
US20030165473A1 (en) * 2001-11-09 2003-09-04 Rush-Presbyterian-St. Luke's Medical Center Engineered intervertebral disc tissue
GB0129008D0 (en) * 2001-12-04 2002-01-23 Univ London Method for forming matrices of hardened material
US6852331B2 (en) * 2002-02-11 2005-02-08 Taipei Biotechnology Ltd., Inc. Fabrication of a cartilage implant
EP1501452A4 (en) * 2002-05-01 2008-02-27 Verigen Ag Injectable chondrocyte implant
US7931687B2 (en) 2002-05-13 2011-04-26 Articular Engineering, Llc Tissue engineered osteochondral implant
JP2003038635A (en) * 2002-06-10 2003-02-12 Olympus Optical Co Ltd Osteochondroimplant material
US7066960B1 (en) * 2002-06-28 2006-06-27 Dickman Curtis A Intervertebral disk replacement
US6958078B2 (en) * 2002-08-19 2005-10-25 The University Of Toledo Bioartificial intervertebral disc
KR101095771B1 (en) * 2002-09-18 2011-12-21 워쏘우 오르쏘페딕 인코포레이티드 Natural tissue devices and methods of implantation
JP4923235B2 (en) * 2002-12-06 2012-04-25 独立行政法人産業技術総合研究所 Bone - Play for transplantation of cartilage tissue
EP1594421A4 (en) * 2003-01-17 2006-02-08 Psinergi Corp Artificial nucleus pulposus and method of injecting same
JP2004283371A (en) * 2003-03-20 2004-10-14 Nagoya Industrial Science Research Inst Medical material
US20050013870A1 (en) * 2003-07-17 2005-01-20 Toby Freyman Decellularized extracellular matrix of conditioned body tissues and uses thereof
US7309359B2 (en) * 2003-08-21 2007-12-18 Warsaw Orthopedic, Inc. Allogenic/xenogenic implants and methods for augmenting or repairing intervertebral discs
US8529625B2 (en) 2003-08-22 2013-09-10 Smith & Nephew, Inc. Tissue repair and replacement
DE10339953B3 (en) * 2003-08-27 2005-04-21 Coripharm Medizinprodukte Gmbh & Co. Kg. Implant material for bone and cartilage replacement and its use
GB0320691D0 (en) * 2003-09-04 2003-10-01 Smith & Nephew Use of joint lining cells for articular cartilage repair
US7927599B2 (en) 2003-09-08 2011-04-19 Ethicon, Inc. Chondrocyte therapeutic delivery system
US7897384B2 (en) * 2003-09-08 2011-03-01 Ethicon, Inc. Chondrocyte therapeutic delivery system
EP2338442B1 (en) 2003-12-11 2013-01-30 Isto Technologies Inc. Particulate cartilage system
US20060275273A1 (en) * 2004-02-20 2006-12-07 Seyedin Mitchell S Intervertebral Disc Repair, Methods and Devices Therefor
WO2005081870A3 (en) * 2004-02-20 2006-12-14 Iv H Davis Adkisson Intervertebral disc repair, methods and devices therefor
WO2005110050A3 (en) * 2004-05-11 2006-06-29 Synthasome Inc Tissue scaffold
US7931894B2 (en) 2004-07-30 2011-04-26 Otsuka Pharmaceutical Co., Ltd. Method of three-dimensionally culturing chondrocytes
DE102004046364A1 (en) * 2004-09-24 2006-03-30 Intox Gmbh A method for determining DNA damage and multi-compartment vessel
US20090221076A1 (en) * 2005-03-01 2009-09-03 Gc Corporation Method of fabricating sheet for cartilage tissue regeneration
GB0516846D0 (en) * 2005-08-17 2005-09-21 Knight David P Meniscal repair device
WO2007025290A3 (en) 2005-08-26 2007-10-18 H Davis Adkisson Iv Implants and methods for repair, replacement and treatment of joint disease
EP2796544A1 (en) 2005-09-09 2014-10-29 Duke University Tissue engineering methods and compositions
CA2623106C (en) 2005-09-19 2013-12-24 Histogenics Corp. Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
US9005646B2 (en) 2005-10-12 2015-04-14 Lifenet Health Compositions for repair of defects in tissues, and methods of making the same
US7906333B2 (en) * 2005-12-27 2011-03-15 Industrial Technology Research Institute Surface modification of polysaccharide, the modified polysaccharide, and method of culturing and recovery cells using the same
US20070156238A1 (en) 2005-12-29 2007-07-05 Industrial Technology Research Institute Multi-layered matrix, method of tissue repair using the same, and multi-layered implant prepared thereof
US20070178137A1 (en) * 2006-02-01 2007-08-02 Toby Freyman Local control of inflammation
EP1988942B1 (en) * 2006-03-01 2011-07-27 FMC Biopolymer AS Gelled composite
US9259445B2 (en) 2006-06-07 2016-02-16 Universidad Tecnica Federico Santa Maria Integrated implant system (IIS) biocompatible, biodegradable and bioactive, comprising a biocompatible sterile porous polymeric matrix and a gel, integrating in situ the tridimensional matrix structure
WO2007141028A3 (en) * 2006-06-07 2008-01-31 Alvarez Alexis Roobin Aceituno Integrated implant system (iis) biocompatible, biodegradable and bioactive, comprising a biocompatible sterile porous polymeric matrix and a gel, integrating in situ the tridimensional matrix structure
WO2008006658A1 (en) * 2006-07-14 2008-01-17 Fmc Biopolymer As Hydrogels containing low molecular weight alginates and biostructures made therefrom
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
US20080255665A1 (en) * 2007-04-11 2008-10-16 Active Implants Corporation Anchored prosthetic meniscus device
CA2684040C (en) 2007-04-12 2016-12-06 Isto Technologies, Inc. Method of forming an implant using a mold that mimics the shape of the tissue defect site and implant formed therefrom
US8257963B2 (en) * 2007-06-01 2012-09-04 Depuy Mitek, Inc. Chondrocyte container and method of use
WO2008157318A3 (en) * 2007-06-13 2009-02-12 Therese Andersen Alginate coated, polysaccharide gel-containing foam composite, preparative methods, and uses thereof
US20090054984A1 (en) 2007-08-20 2009-02-26 Histogenics Corporation Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
US8685107B2 (en) 2007-07-03 2014-04-01 Histogenics Corporation Double-structured tissue implant and a method for preparation and use thereof
EP2182887B1 (en) * 2007-08-20 2016-12-14 Histogenics Corporation A method for improvement of differentiation of mesenchymal stem cells using a double-structured tissue implant
CA2718174A1 (en) * 2008-03-03 2009-09-11 William Marsh Rice University Methods of fabricating enhanced tissue-engineered cartilage
CA2729917C (en) 2008-07-06 2016-09-13 The Curators Of The University Of Missouri Osteochondral implants, arthroplasty methods, devices, and systems
US9132208B2 (en) * 2008-08-07 2015-09-15 Lifenet Health Composition for a tissue repair implant and methods of making the same
DE102008054245A1 (en) * 2008-10-24 2010-04-29 Aesculap Ag Fixation element for fixating tissue and / or implants
US20100331865A1 (en) * 2009-06-30 2010-12-30 Gino Bradica Biphasic implant device providing joint fluid therapy
US9744123B2 (en) * 2009-06-30 2017-08-29 Kensey Nash Corporation Biphasic implant device providing gradient
US20100331998A1 (en) * 2009-06-30 2010-12-30 Ringeisen Timothy A Electrokinetic device for tissue repair
US9399086B2 (en) 2009-07-24 2016-07-26 Warsaw Orthopedic, Inc Implantable medical devices
JP2011160817A (en) * 2010-02-04 2011-08-25 Univ Of Tokyo Implantation support material
US9144629B2 (en) * 2010-03-03 2015-09-29 Novabone Products, Llc Ionically crosslinked materials and methods for production
US9034048B2 (en) * 2011-01-26 2015-05-19 John A. Choren Orthopaedic implants and methods of forming implant structures
US8771353B2 (en) 2011-03-08 2014-07-08 DePuy Synthes Products, LLC Method and implant for replacing damaged meniscal tissue
JP5896612B2 (en) * 2011-03-17 2016-03-30 サンスター株式会社 Cell scaffold
JP6182135B2 (en) 2011-06-06 2017-08-16 レゲネシス ベーフェーベーアー Amplification of stem cells in a hollow fiber bioreactor
US9381112B1 (en) 2011-10-06 2016-07-05 William Eric Sponsell Bleb drainage device, ophthalmological product and methods
US8632489B1 (en) 2011-12-22 2014-01-21 A. Mateen Ahmed Implantable medical assembly and methods
WO2017066822A1 (en) * 2015-10-19 2017-04-27 Skin Tissue Engineering Pty Ltd Porous matrix with incorporated cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007934A (en) * 1987-07-20 1991-04-16 Regen Corporation Prosthetic meniscus
US5108438A (en) * 1989-03-02 1992-04-28 Regen Corporation Prosthetic intervertebral disc
US5306311A (en) * 1987-07-20 1994-04-26 Regen Corporation Prosthetic articular cartilage
US4880429A (en) * 1987-07-20 1989-11-14 Stone Kevin R Prosthetic meniscus
US5681353A (en) * 1987-07-20 1997-10-28 Regen Biologics, Inc. Meniscal augmentation device
FR2657352B1 (en) * 1990-01-25 1993-08-13 France Etat Armement New biologic replacement of connective tissue, a composite structure based on collagen, and process for its preparation.
US5855608A (en) * 1994-05-13 1999-01-05 Thm Biomedical, Inc. Device and methods for in vivo culturing of diverse tissue cells
GB9503492D0 (en) * 1995-02-22 1995-04-12 Ed Geistlich S Hne A G F R Che Chemical product
DE69631490D1 (en) * 1995-11-09 2004-03-11 Univ Massachusetts Boston Restoration of the tissue surface with compositions of hydrogel-cell
WO1997045532A1 (en) * 1996-05-28 1997-12-04 Brown University Research Foundation Hyaluronan based biodegradable scaffolds for tissue repair
US5916585A (en) * 1996-06-03 1999-06-29 Gore Enterprise Holdings, Inc. Materials and method for the immobilization of bioactive species onto biodegradable polymers

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050186673A1 (en) * 1995-02-22 2005-08-25 Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie Collagen carrier of therapeutic genetic material, and method
US20080268053A1 (en) * 1995-02-22 2008-10-30 Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie Collagen carrier of therapeutic genetic material, and method
US9034315B2 (en) 1997-10-10 2015-05-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Cell-charged multi-layer collagen membrane
US20080107710A1 (en) * 1997-10-10 2008-05-08 Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie Collagen carrier of therapeutic genetic material and method
US20070031388A1 (en) * 1997-10-10 2007-02-08 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Cell-charged multi-layer collagen membrane
US8911763B2 (en) 1997-10-10 2014-12-16 Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie Collagen carrier of therapeutic genetic material and method
US20060159668A1 (en) * 1997-10-10 2006-07-20 Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie Resorbable extracellular matrix for reconstruction of bone
US20050186283A1 (en) * 1997-10-10 2005-08-25 Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie Collagen carrier of therapeutic genetic material, and method
US8858981B2 (en) 1997-10-10 2014-10-14 Ed. Geistlich Soehne Fuer Chemistrie Industrie Bone healing material comprising matrix carrying bone-forming cells
US8449561B2 (en) 1999-07-23 2013-05-28 Depuy Mitek, Llc Graft fixation device combination
US8016867B2 (en) 1999-07-23 2011-09-13 Depuy Mitek, Inc. Graft fixation device and method
US20040133275A1 (en) * 2000-03-27 2004-07-08 Mansmann Kevin A. Implants for replacing cartilage, with negatively-charged hydrogel surfaces and flexible matrix reinforcement
US9314339B2 (en) * 2000-03-27 2016-04-19 Formae, Inc. Implants for replacing cartilage, with negatively-charged hydrogel surfaces and flexible matrix reinforcement
US20040063200A1 (en) * 2000-07-28 2004-04-01 Elliot Chaikof Biological component comprising artificial membrane
US7713544B2 (en) * 2000-07-28 2010-05-11 Emory University Biological component comprising artificial membrane
US8691259B2 (en) 2000-12-21 2014-04-08 Depuy Mitek, Llc Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration
US8690874B2 (en) 2000-12-22 2014-04-08 Zimmer Orthobiologics, Inc. Composition and process for bone growth and repair
EP1338291A3 (en) * 2002-02-21 2003-11-19 Ed. Geistlich Söhne Ag Für Chemische Industrie Resorbable extracellular matrix for reconstruction of bone
EP1338291A2 (en) * 2002-02-21 2003-08-27 Ed. Geistlich Söhne Ag Für Chemische Industrie Resorbable extracellular matrix for reconstruction of bone
EP1938845A3 (en) * 2002-02-21 2008-11-12 Ed Geistlich Söhne AG Für Chemische Industrie Resorbable extracellular matrix for reconstruction of bone
US8262731B2 (en) 2002-05-23 2012-09-11 Pioneer Surgical Technology, Inc. Artificial disc device
US20030220691A1 (en) * 2002-05-23 2003-11-27 Pioneer Laboratories, Inc. Artificial intervertebral disc device
US9351852B2 (en) 2002-05-23 2016-05-31 Pioneer Surgical Technology, Inc. Artificial disc device
US8241360B2 (en) 2002-05-23 2012-08-14 Pioneer Surgical Technology, Inc. Artificial disc device
US8388684B2 (en) 2002-05-23 2013-03-05 Pioneer Signal Technology, Inc. Artificial disc device
US20050197707A1 (en) * 2002-09-18 2005-09-08 Trieu Hai H. Collagen-based materials and methods for augmenting intervertebral discs
US20040228901A1 (en) * 2002-09-18 2004-11-18 Trieu Hai H. Collagen-based materials and methods for treating synovial joints
US7744651B2 (en) 2002-09-18 2010-06-29 Warsaw Orthopedic, Inc Compositions and methods for treating intervertebral discs with collagen-based materials
US7713303B2 (en) 2002-09-18 2010-05-11 Warsaw Orthopedic, Inc. Collagen-based materials and methods for augmenting intervertebral discs
US9511171B2 (en) 2002-10-18 2016-12-06 Depuy Mitek, Llc Biocompatible scaffolds with tissue fragments
US8637066B2 (en) 2002-10-18 2014-01-28 Depuy Mitek, Llc Biocompatible scaffold for ligament or tendon repair
US7824701B2 (en) 2002-10-18 2010-11-02 Ethicon, Inc. Biocompatible scaffold for ligament or tendon repair
US7731981B2 (en) 2002-11-15 2010-06-08 Warsaw Orthopedic, Inc. Collagen-based materials and methods for treating synovial joints
US20070134343A1 (en) * 2002-11-15 2007-06-14 Trieu Hai H Collagen-based materials and methods for treating synovial joints
US9486558B2 (en) 2003-03-27 2016-11-08 Locate Therapeutics Limited Porous matrix
US20060263335A1 (en) * 2003-03-27 2006-11-23 Regentec Ltd. Porous matrix
US8226715B2 (en) 2003-06-30 2012-07-24 Depuy Mitek, Inc. Scaffold for connective tissue repair
US9211362B2 (en) 2003-06-30 2015-12-15 Depuy Mitek, Llc Scaffold for connective tissue repair
US20050038520A1 (en) * 2003-08-11 2005-02-17 Francois Binette Method and apparatus for resurfacing an articular surface
US9445916B2 (en) 2003-10-22 2016-09-20 Pioneer Surgical Technology, Inc. Joint arthroplasty devices having articulating members
US20080071385A1 (en) * 2003-11-26 2008-03-20 Depuy Mitek, Inc. Conformable tissue repair implant capable of injection delivery
US7875296B2 (en) 2003-11-26 2011-01-25 Depuy Mitek, Inc. Conformable tissue repair implant capable of injection delivery
US8496970B2 (en) 2003-11-26 2013-07-30 Depuy Mitek, Llc Conformable tissue repair implant capable of injection delivery
US8137702B2 (en) 2003-11-26 2012-03-20 Depuy Mitek, Inc. Conformable tissue repair implant capable of injection delivery
US20050125077A1 (en) * 2003-12-05 2005-06-09 Harmon Alexander M. Viable tissue repair implants and methods of use
US7901461B2 (en) 2003-12-05 2011-03-08 Ethicon, Inc. Viable tissue repair implants and methods of use
US20110177134A1 (en) * 2003-12-05 2011-07-21 Depuy Mitek, Inc. Viable Tissue Repair Implants and Methods of Use
US8641775B2 (en) * 2003-12-05 2014-02-04 Depuy Mitek, Llc Viable tissue repair implants and methods of use
US20050209606A1 (en) * 2004-02-26 2005-09-22 Dharmendra Jani Alginate viscoelastic composition, method of use and package
WO2005082333A1 (en) * 2004-02-26 2005-09-09 Bausch & Lomb Incorporated Alginate viscoelastic composition, method of use and package
US8221780B2 (en) 2004-04-20 2012-07-17 Depuy Mitek, Inc. Nonwoven tissue scaffold
US8137686B2 (en) 2004-04-20 2012-03-20 Depuy Mitek, Inc. Nonwoven tissue scaffold
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
US20060200245A1 (en) * 2005-03-07 2006-09-07 Sdgi Holdings, Inc. Materials, devices, and methods for in-situ formation of composite intervertebral implants
WO2006136905A2 (en) * 2005-06-20 2006-12-28 Giuseppe Calvosa Biocompatible composition for replacing/regenerating tissues
US20090136576A1 (en) * 2005-06-20 2009-05-28 Giuseppe Calvosa Biocompatible composition for replacing/regenerating tissues
WO2006136905A3 (en) * 2005-06-20 2007-05-31 Nunzia Bernardini Biocompatible composition for replacing/regenerating tissues
US20090306687A1 (en) * 2005-10-31 2009-12-10 Life Spring Biotech Co., Ltd. Scleral buckling band and method for making the same
WO2007057908A3 (en) * 2005-11-21 2009-04-09 Alexander Dubson Spinal nucleus prosthesis device
US20070156174A1 (en) * 2006-01-03 2007-07-05 Arthrotek, Inc. Method and apparatus for repairing a meniscus
US8118779B2 (en) 2006-06-30 2012-02-21 Warsaw Orthopedic, Inc. Collagen delivery device
US20080004431A1 (en) * 2006-06-30 2008-01-03 Warsaw Orthopedic Inc Method of manufacturing an injectable collagen material
US8399619B2 (en) 2006-06-30 2013-03-19 Warsaw Orthopedic, Inc. Injectable collagen material
US20080004703A1 (en) * 2006-06-30 2008-01-03 Warsaw Orthopedic, Inc. Method of treating a patient using a collagen material
US20100040667A1 (en) * 2006-09-07 2010-02-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treating bone cancer
US9693872B2 (en) 2006-09-15 2017-07-04 Pioneer Surgical Technology, Inc. Intervertebral disc implant
US9233011B2 (en) 2006-09-15 2016-01-12 Pioneer Surgical Technology, Inc. Systems and apparatuses for inserting an implant in intervertebral space
US9655730B2 (en) 2006-10-09 2017-05-23 Active Implants LLC Meniscus prosthetic device
US8192491B2 (en) 2006-10-09 2012-06-05 Active Implants Corporation Meniscus prosthetic device
US9320606B2 (en) 2006-10-09 2016-04-26 Active Implants LLC Meniscus prosthetic device
US8282911B2 (en) 2006-10-23 2012-10-09 ETH Zürich Implant material
US20100196440A1 (en) * 2006-10-23 2010-08-05 Eth Zurich Implant Material
US20080152687A1 (en) * 2006-12-21 2008-06-26 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US8742072B2 (en) 2006-12-21 2014-06-03 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US7718616B2 (en) 2006-12-21 2010-05-18 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US20090259312A1 (en) * 2008-04-09 2009-10-15 Active Implants Corporation Meniscus Prosthetic Devices with Anti-Migration Features
US9326863B2 (en) 2008-04-09 2016-05-03 Active Implants LLC Meniscus prosthetic device selection and implantation methods
US7991599B2 (en) 2008-04-09 2011-08-02 Active Implants Corporation Meniscus prosthetic device selection and implantation methods
US7611653B1 (en) 2008-04-09 2009-11-03 Active Implants Corporation Manufacturing and material processing for prosthetic devices
US8361147B2 (en) 2008-04-09 2013-01-29 Active Implants Corporation Meniscus prosthetic devices with anti-migration features
US20090259313A1 (en) * 2008-04-09 2009-10-15 Active Implants Corporation Manufacturing and material processing for prosthetic devices
US8016884B2 (en) 2008-04-09 2011-09-13 Active Implants Corporation Tensioned meniscus prosthetic devices and associated methods
US20110004305A1 (en) * 2009-07-06 2011-01-06 Aesculap Ag Elevated implant for the reconstruction of meniscus defects or partial meniscus defects
US9445908B2 (en) 2009-07-06 2016-09-20 Aesculap Ag Elevated implant for the reconstruction of meniscus defects or partial meniscus defects
US20130110245A1 (en) * 2010-03-30 2013-05-02 3T Textiltechnologietransfer Gmbh Implant having a sandwich structure, implant system and implant support
US8790699B2 (en) * 2010-04-23 2014-07-29 Warsaw Orthpedic, Inc. Foam-formed collagen strand
US9771410B2 (en) 2010-04-23 2017-09-26 Warsaw Orthopedic, Inc. Foam-formed collagen strand
US20110262541A1 (en) * 2010-04-23 2011-10-27 Osteotech, Inc. Foam-formed collagen strand
US8613938B2 (en) 2010-11-15 2013-12-24 Zimmer Orthobiologics, Inc. Bone void fillers
US9241807B2 (en) 2011-12-23 2016-01-26 Pioneer Surgical Technology, Inc. Systems and methods for inserting a spinal device
WO2014011891A1 (en) * 2012-07-11 2014-01-16 Osiris Therapeutics, Inc. Methods of manufacturing cartilage products

Also Published As

Publication number Publication date Type
JP2001514551A (en) 2001-09-11 application
US6306169B1 (en) 2001-10-23 grant
EP1019109A1 (en) 2000-07-19 application
WO1998040111A1 (en) 1998-09-17 application
GB9704749D0 (en) 1997-04-23 grant

Similar Documents

Publication Publication Date Title
Sittinger et al. Current strategies for cell delivery in cartilage and bone regeneration
Shao et al. Evaluation of a hybrid scaffold/cell construct in repair of high-load-bearing osteochondral defects in rabbits
Guo et al. Repair of large articular cartilage defects with implants of autologous mesenchymal stem cells seeded into β-tricalcium phosphate in a sheep model
Mandal et al. Multilayered silk scaffolds for meniscus tissue engineering
Niederauer et al. Evaluation of multiphase implants for repair of focal osteochondral defects in goats
Glowacki et al. Collagen scaffolds for tissue engineering
US6472210B1 (en) Polymer scaffold having microporous polymer struts defining interconnected macropores
US6425918B1 (en) Polysaccharide sponges for cell culture and transplantation
US6991652B2 (en) Tissue engineering composite
US6569442B2 (en) Preparation of polymer foam having gelled sol coating for intervertebral disc reformation
Thomson et al. Biodegradable polymer scaffolds to regenerate organs
US6005161A (en) Method and device for reconstruction of articular cartilage
US7901461B2 (en) Viable tissue repair implants and methods of use
US6652872B2 (en) Scaffold formed of tissue treated to eliminate cellular and cytosolic elements
US6949252B2 (en) Method for preparing an implantable multilayer tissue construct
US7476250B1 (en) Semi-permeable membranes to assist in cartilage repair
US5904717A (en) Method and device for reconstruction of articular cartilage
US6730252B1 (en) Methods for fabricating a filament for use in tissue engineering
EP1532991A1 (en) Scaffold material for regeneration of hard tissue/soft tissue interface
US7022522B2 (en) Macroporous polymer scaffold containing calcium phosphate particles
Kang et al. A new biodegradable polyester elastomer for cartilage tissue engineering
US5624463A (en) Prosthetic articular cartilage
Swieszkowski et al. Repair and regeneration of osteochondral defects in the articular joints
US6511511B1 (en) Fiber-reinforced, porous, biodegradable implant device
Freed et al. Joint resurfacing using allograft chondrocytes and synthetic biodegradable polymer scaffolds